Hematoma intraparenquimatoso del sistema nervioso central asociado con dasatinib en el tratamiento de leucemia mieloide crónica en fase acelerada. Presentación de dos casos y revisión de la literatura / Intraparenchymal haematoma of the central nervous system associated with Dasatinib in the treatment of chronic myeloid leukaemia in accelerated phase. Presentation of two cases and review of literature

Resumen Se presentan dos casos clínicos de pacientes con leucemia mieloide crónica en fase acelerada, hospitalizados para inicio de terapia dirigida con inhibidores de tirosina cinasa (dasatinib). Posteriormente se determina la presencia de sangrado intraparenquimatoso a sistema nervioso central. Para finalizar, se revisa la literatura disponible a cerca de eventos adversos tipo sangrado asociados a dasatinib y los posibles condicionantes de este desenlace.

Abstract Two clinical cases are presented on patients with chronic myeloid leukaemia in accelerated phase, who were admitted to hospital for initiation of targeted therapy with tyrosine kinase inhibitors (Dasatinib). Intraparenchymal bleeding in the central nervous system was subsequently observed. A review was also made on the available literature on bleeding-related adverse events associated with Dasatinib and the possible determining factors of this outcome.